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Abstract
Nearly all bacteria contain a peptidoglycan cell wall. The peptidoglycan precursor molecule
is LipidII, containing the basic peptidoglycan building block attached to a lipid. Although the
suitability of LipidII as an antibacterial target has long been recognized, progress on eluci-
dating the role(s) of LipidII in bacterial cell biology has been slow. The focus of this review is
on exciting new developments, both with respect to antibacterials targeting LipidII as well as
the emerging role of LipidII in organizing the membrane and cell wall synthesis. It appears
that on both sides of the membrane, LipidII plays crucial roles in organizing cytoskeletal pro-
teins and peptidoglycan synthesis machineries. Finally, the recent discovery of no less than
three different categories of LipidII flippases will be discussed.
Peptidoglycan (PG), the main component of the cell wall, is a structure unique to bacteria. Cur-
rently, over 50% of the antibiotics in use target bacterial cell wall synthesis, and thus PG synthe-
sis is considered the Achilles’ heel of bacteria [1]. The precursor of PG is LipidII, a lipid-linked
disaccharide with a pentapeptide side chain. Linkage of the disaccharide to a growing glycan
strand results in release of the lipid anchor and leaves the pentapeptide free for crosslinking to
peptides on other glycan strands or for processing. Various excellent reviews describe the syn-
thesis of LipidII, the incorporation of LipidII into PG, and the use of LipidII as a target for anti-
bacterials [2–6]. LipidII’s conserved structure makes it difficult for pathogens to develop
resistance against LipidII targeting molecules. This review focuses on the latest findings on
antibacterials targeting LipidII, such as teixobactin [7], and on new LipidII biology (summa-
rized in Fig 1). It is becoming more and more evident that LipidII is not just a passive brick
that is being added to the cell wall but rather plays a key role in organization of the membrane.
LipidII in Pathogens and As a Target for Antibacterials
Cell wall biosynthesis inhibitors are the most used antibacterial drugs worldwide, and the
essentiality and uniqueness of the bacterial cell wall make it an ideal target for antibiotics [1].
LipidII is a particularly attractive target, as it is highly conserved and difficult to modify [1,8].
PG is even more ubiquitous than was thought. Recently, the Chlamydia anomaly—the observa-
tion that Chlamydia has no detectable PG but is sensitive to penicillin—was solved by novel
fluorescent labeling methods that showed that these bacteria do indeed contain peptidoglycan
[9,10]. That Chlamydiae (and Wolbachia) contain LipidII was already known [11], but LipidII
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was thought to be only required to organize cellular processes such as division in these
organisms.
Various classes of compounds target LipidII (Fig 1), including (i) glycopeptides, like vanco-
mycin, that bind the last two D-amino acid residues of the pentapeptide blocking crosslinking
[12]—though hydrophobic derivatives of vancomycin also block transglycosylation [13]; (ii)
unmodified peptides, like defensins, which are part of the innate immune system [14]; (iii) lan-
tibiotics, such as nisin, which are peptides that contain thioether rings formed by posttransla-
tional modification, [15]; and (iv) depsipeptides, like teixobactin, which are nonribosomally
synthesized peptides [16]. In addition, various compounds inhibit the synthesis of LipidII (D-
cycloserine, fosfomycin, tunicamycin) or the recycling of the undecaprenol carrier molecule,
which results in depletion of LipidII (bacitracin) [1].
Recently, teixobactin, a LipidII-targeting antibiotic isolated from the gram-negative soil bac-
terium Eleftheria terrae, was discovered [7]. Teixobactin is a nonribosomally synthesized depsi-
peptide that binds the pyrophosphate-sugar moiety of undecaprenyl-bound cell wall
precursors such as LipidI, II, and III (precursor for wall teichoic acid), thus preventing synthe-
sis of the cell wall and killing the cells. Teixobactin is active against several gram-positive bacte-
ria and kills pathogens, includingMycobacterium tuberculosis, Staphylococcus aureus, and
various drug-resistant strains, possibly without development of resistance [7]. Unlike various
other peptides that target LipidII, teixobactin is very stable and has low toxicity, making it one
of the most promising antibacterial compounds discovered in the last three decades.
In the last few years, a number of papers have been published on the mechanism of lantibio-
tics, short peptides containing lanthionine and methyl-lanthionine rings [17]. Two classes are
distinguished: Class A lantibiotics that have elongated structures and Class B lantibiotics with
globular structures. Nisin is the most well-known Class A lantibiotic. Class A lantibiotics con-
tain a “pyrophosphate cage” consisting of two lanthionine rings that bind LipidII [18], which
Fig 1. Organization of cell wall synthesis by LipidII.Overview of recent work that highlights various new insights about the role of LipidII; for example, (1)
in the identification of novel antibacterials that target LipidII (including teixobactin and bacteriocins), (2) how LipidII is translocated over the membrane by
different families of flippases (such as FtsW or RodA, MurJ, and Amj), (3) how it is recruited to regions of increased fluidity (RIFs) and how it organizes
attachment of MreB(-like) filaments, and (4) how cell wall synthesis enzymes (penicillin-binding proteins [PBPs]) are recruited to LipidII.
doi:10.1371/journal.ppat.1005213.g001
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results in insertion of the elongated peptide in the membrane and the formation of large, stable
pores composed of four LipidII and eight nisin molecules [8]. Pore formation is sufficient to
kill cells, but the binding to the LipidII pyrophosphate moiety prevents LipidII incorporation
into glycan strands, a second killing mechanism [19]. The binding of nisin to LipidII also
results in the formation of clusters of LipidII in the membrane, removing LipidII from the nor-
mal sites of PG synthesis [20]. Formation of these clusters is concomitant with pore formation,
and these pores are sufficient to kill L-forms, cells that proliferate without an intact cell wall
[21]. Class B lantibiotics, such as mersacidin, bind to LipidII but do not form membrane pores.
The unavailability of LipidII for incorporation into PG and the sequestration of the undecapre-
nol carrier molecule are sufficient to kill the cell.
Several two-component lantibiotics were recently discovered, such as Lacticin 3147 [22]
and haloduracin [23]. These lantibiotics act synergistically: both components are needed for
killing. It is thought that the first component, which is structurally similar to mersacidin, binds
to LipidII and triggers a conformational change that enables binding of the second component,
which has a high similarity with the C-terminal tail of nisin, resulting in pore formation and
cell death [24]. The hybrid lantibiotic microbisporicin (commercially developed as NAI-107)
combines these two components in one molecule [25,26]. The C-terminal part of microbispori-
cin is similar to the C-terminal parts of nisin and gallidermin, while the N-terminal part resem-
bles mersacidin. These newly discovered lantibiotics increase our understanding of the
mechanism of known lantibiotics, and are also important candidates for clinical development.
Resistance against antibacterials that target LipidII does not develop easily. Vancomycin
resistance occurs by replacement of the terminal D-Ala-D-Ala part of the pentapeptide with
D-Ala-D-Lac and appeared only after 30 years of use in the clinic [27]. The pyrophosphate and
the adjacent MurNAc sugar group of LipidII are highly conserved, and resistance development
against antibacterials targeting this site of LipidII is expected to be even tougher. For instance,
nisin has been used for more than four decades in the food industry without significant resis-
tance development [15]. Also, various pathogens failed to develop resistance against the
recently discovered teixobactin [7]. These classes of antibacterials are promising therapeutics,
although teixobactin and lantibiotics only target LipidII in gram-positive bacteria, as they do
not pass the outer membrane in gram-negatives.
Flipping LipidII across the Cytoplasmic Membrane
LipidII synthesis in the cytoplasm and its incorporation into PG are well characterized, yet
how LipidII is flipped across the membrane has long remained a mystery. Recent work by the
Breukink, Ruiz, Bernhardt, and Rudner labs has identified three different protein classes that
can translocate LipidII: FtsW (and its homologue RodA), MurJ, and Amj.
FtsW and RodA are members of the Shape, Elongation, Divison, and Sporulation (SEDS)
protein family, which is conserved among PG-containing bacteria but absent from some wall-
less bacteria or archaea [28]. The ftsW and rodA genes code for integral membrane proteins
(IMP) that generally contain ten transmembrane α-helical segments (TMS), thus fitting a
transport protein function, and are often organized in an operon structure with a cognate
transpeptidase that is required for correct PG organization. The FtsW-transpeptidase combina-
tion is required for PG synthesis at the division site and depends on FtsZ for localization
[29,30], whereas the RodA-transpeptidase combination functions in sidewall synthesis; the
interaction between RodA and its cognate transpeptidase is dependent on active MreB [31,32]
in bacteria in which MreB homologues are present. The Breukink lab synthesized a fluorescent
LipidII analogue for use in in vitro flipping assays with membrane vesicles or proteoliposomes
[33]. The amount of FtsW in membrane vesicles determined the amount of LipidII
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translocated, and reconstitution of purified FtsW in proteoliposomes showed that FtsW is suf-
ficient to mediate LipidII translocation. Control proteins such as KcsA and SecYEG, as well as
MurJ, did not transport LipidII [33]. Strikingly, TMS5–TMS10 are not required for in vitro
LipidII transport, but two positively charged residues in TMS4 are critical for in vitro LipidII
transport and in vivo FtsW function [34].
MurJ was identified in a bioinformatics search for possible LipidII flippases as an essential
Escherichia coli gene coding for an IMP that is a member of the multidrug/oligosaccharidyl-
lipid/polysaccharide (MOP) exporter superfamily, which includes transporters of other unde-
caprenyl-linked molecules. MurJ is conserved amongst PG containing bacteria but absent from
bacteria that do not have PG [35]. Cells depleted formurJ show severe shape defects and have
reduced incorporation of new PG material [35–37]. MurJ contains 14 TMS and its structure
has been modeled, revealing a hydrophilic cavity containing charged residues that are essential
for MurJ function [38,39]. The Ruiz and Bernhardt labs developed an in vivo flippase assay in
which radiolabeled LipidII is cleaved after translocation by externally added ColM (a toxin that
cleaves LipidII that is exposed in the periplasm). Both the ColM cleavage product and mem-
brane associated LipidII can be detected, and the rationale of the assay is that a block of LipidII
translocation results in a decrease of ColM cleavage product with a concomitant increase of
LipidII in the membrane. Cells that expressed MurJ displayed LipidII transport activity, and,
importantly, cells expressing a MurJ variant that could be chemically inactivated were blocked
in LipidII translocation when the inactivator was added [40]. In this assay, LipidII translocation
also occurred when the SEDS proteins RodA and FtsW were absent from the cell [40].
An exciting recent paper indicates that there is at least a third class of LipidII flippases.
Bacillus subtilis is perfectly viable without its four most obvious MurJ paralogs [41], but even a
strain lacking all ten MOP family members is viable [42]. This MOP-less strain allowed Rudner
and colleagues to identify Amj (alternate to MurJ) as a novel type of LipidII translocase. Amj is
synthetically lethal with ytgP, the MOP identified as the major B. subtilis murJ (MurJBsu)
homolog, indicating that these genes have redundant functions [42]. Amj and MurJBsu are both
capable of rescuing an E. coli murJ deletion, and Amj functions in the ColM-LipidII flipping
assay [42]. Amj is predicted to have six TMS and is neither a MOP family member nor an
ATP-Binding Cassette (ABC) transporter. Amj is not widely conserved, yet it is present in sub-
sets of both gram-positive and -negative bacteria.
It is difficult to reconcile the in vitro and in vivo flippase assays’ results. Each assay shows
activity only for either FtsW and RodA or for MurJ and Amj (not tested in vitro). Inactivation
of either FtsW or MurJ through a point mutation or a chemical modification abolishes its activ-
ity in the respective assay. From a biochemist’s perspective, the in vitro translocation assay [33]
using proteoliposomes which contain only FtsW or MurJ is very clean, but MurJ may have
inadvertently been inactivated during purification and reconstitution, precluding the measure-
ment of MurJ activity. The in vivo assay [40] is equally elegant, but as it uses whole cells (or
spheroplasts), it also leaves room for other explanations of the observations. What if LipidII
uses both protein classes for transport, with different kinetics? The ColM assay requires LipidII
to be available for ColM—if FtsW and/or RodA quickly hands over LipidII to its cognate trans-
peptidase for incorporation into PG, this might preclude ColM cleavage. MurJ-translocated
LipidII might be more exposed in the outer leaflet of the membrane, thus allowing ColM to
cleave only the MurJ-associated fraction of LipidII.
The identification of three families of LipidII flippases over the past years indicates tremen-
dous progress and provides new targets for antibacterials. The question of how LipidII is pre-
cisely translocated by these various flippases remains to be resolved.
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LipidII and Membrane Organization
LipidII binding by antibacterial compounds and its incorporation into PG take place at the
outer leaflet of the cytoplasmic membrane. A possible role for LipidII in the inner leaflet of the
membrane has not received much attention. This may change rapidly, as a recent study showed
that LipidII regulates membrane association of the actin homologue MreB in B. subtilis [43].
Membrane association of MreB was known to be dependent on active PG synthesis [44,45],
but the novel study suggests that it is the lack of carrier Lipid molecules that leads to MreB dis-
sociation, not the absence of PG synthesis per se. Blocking synthesis of wall teichoic acid
(WTA), depletion of UppS (required for undecaprenyl-pyrophosphate synthesis), and inhibit-
ing PG synthesis all led to MreB release from the membrane [43]. Depletion of MurG, which
blocks synthesis of LipidII but not of its precursor LipidI, also resulted in MreB delocalization,
suggesting that MreB binds directly to LipidII (Fig 2) [43]. It has to be noted that many of these
treatments alter the flux of substrates through the PG synthesis pathway [46], which could
influence MreB dynamics [44,45] or the localization of other proteins that interact with MreB.
In the case of MurG depletion, overall lipid organization in the membrane is disrupted [47],
which may also cause MreB release.
MreB is required for the generation of fluid lipid membrane domains, so-called regions of
increased fluidity (RIFs) (Fig 3) [48]. LipidII partitions in the more mobile domains of sup-
ported bilayers that contain liquid-crystalline lipid domains segregated from more gel-like lip-
ids [49], thus the presence of increased LipidII in these RIFs makes sense. When MreB and its
Fig 2. LipidII regulatesmembrane association of MreB.Using Total Internal Reflection Fluorescence
(TIRF) microscopy, association and dissociation of MreB-GFP with the membrane can be followed. Upon
depletion of MurG and subsequent halt of conversion of LipidI to LipidII, MreB-GFP is released from the
membrane (upper row); after induction of MurG expression, LipidII production is resumed and MreB-GFP is
re-localized on the membrane (lower row). Shown are snapshots (A, B, D, E) of single TIRF images at the
respective time points and an analysis of the variance in intensity over time (C, F), with red indicating regions
of high protein mobility and blue denoting low mobility. (Adapted with permission fromMacmillan Publishers
Ltd.: Nature Chemical Biology; K. Schirner et al., Nat Chem Biol 11, 38–45 [2015], Macmillan Publishers Ltd.
2015.)
doi:10.1371/journal.ppat.1005213.g002
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homologues Mbl and MreBH are absent, RIFs disappear, and the membrane becomes more
homogeneous—this also affects the diffusion of other membrane proteins [48]. Notably, RIFs
are different from bacterial lipid raft domains [50,51], which are less fluid than the surrounding
material [52].
These two reports raise a paradox: does the presence of LipidII recruit MreB, or does MreB
organize the membrane so that LipidII is recruited to domains to facilitate active PG synthesis
—or is it a bit of both? Bacteria that lack MreB, such as Staphylococcus aureus and Corynebacte-
rium glutamicum, do not organize the membrane in RIFs [48], yet do localize LipidII at sites of
active PG synthesis [53]. MreB, heterologously expressed in S. aureus, forms patches at discrete
regions in the membrane (not at the septum, the normal location of LipidII), and these MreB
patches organize new call wall synthesis, resulting in misshapen cells (Fig 4) [54]. This experi-
ment supports the notion that MreB recruits LipidII, either directly or indirectly. MreB locali-
zation does not solely depend on LipidII but also on various membrane proteins such as MreD
[55,56] and RodZ [57–59]; MreB interacts with key proteins involved in LipidII synthesis [56],
suggesting that a key function of MreB is to coordinate LipidII synthesis at regions where the
membrane environment is “friendly” for LipidII. The presence of sufficient LipidII at these
sites could act as a feedback mechanism that allows MreB dynamics and formation of a protein
complex that drives PG synthesis along the lateral wall [43], and depletion of the LipidII pool
in the membrane would result in a (temporary) halt of PG synthesis until order is restored
[44,45,60].
Fig 3. MreB is required for the generation of regions of increased fluidity (RIFs).GFP-MreB (green;
panel B, C) co-localizes with regions of increased fluidity (RIFs, stained with the lipid-dye DiI-C12, red; panel
A, C) in a ΔMreBCD strain of B. subtilis (cells look round because of the resulting shape defect). (Adapted
with permission from H. Strahl, F. Burmann, L. W. Hamoen, The actin homologue MreB organizes the
bacterial cell membrane.Nat Commun 5, 3442 [2014].)
doi:10.1371/journal.ppat.1005213.g003
Fig 4. Expression of MreB in the non-MreB–containing bacterium S. aureus leads to accumulation of
MreB and peptidoglycan. Patches of MreB are formed (red, panel C), leading to aberrant production of
peptidoglycan (asterisks, panel B). Wild type cells are shown for comparison (panel A). (Amended with
permission from American Society for Microbiology from A. Yepes et al., 2014, Appl Environ Microbiol 80,
3868–3878, DOI: 10.1128/AEM.00759-14.)
doi:10.1371/journal.ppat.1005213.g004
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Both studies on MreB recruitment by LipidII [43] and MreB-mediated membrane organiza-
tion [48] were performed in B. subtilis. Membrane attachment of MreB in gram-positive bacte-
ria is mediated by an internal hydrophobic loop, whereas gram-negative MreB contain an
additional N-terminal amphipathic helix that is required for membrane binding [61]. This
may result in a different affinity for the membrane; however, both attachment methods allow
the binding of MreBs to synthetic vesicles devoid of or containing a very low amount of (in the
case of total lipid mixtures) LipidII [61–63]. Such in vitro methods, in which liposomes can be
doped with synthetic LipidII, can be used to further study the role of LipidII in MreB recruit-
ment, the role of MreB in the organization of membrane domains, and the presence of LipidII
in such domains.
Organization of PG Synthesis
LipidII incorporation into PG occurs through a combination of transglycosylation reactions
that attach the disaccharide to glycan strands and transpeptidation reactions that form cross-
links between the pentapeptide chains that are attached to the glycan strands. These reactions
are mediated by the so-called penicillin-binding proteins (PBPs), the targets for beta-lactam
antibiotics. The PBPs are organized in large protein complexes that span the cytoplasmic mem-
brane and that include proteins involved in LipidII synthesis, translocation, and incorporation
into PG—known as the “divisome” for synthesis of the division septum and “elongasome” for
synthesis of lateral cell wall in non-coccoid bacteria [4,64]. The divisome and elongasome are
organized by the cytoskeletal proteins FtsZ and MreB, respectively. Some bacteria, like Chla-
mydia sp., synthesize PG without apparent coordination of cytoskeletal elements [9,10]. But in
organisms that contain cytoskeletal elements, the presence of LipidII plays an important role in
localizing the PG synthesis machinery through a process called substrate availability [65].
Altering LipidII structure, or blocking LipidII binding by PBPs by either vancomycin or β-lac-
tams, leads to delocalization of the critical PBP2 in S. aureus [66]. In Streptococcus pneumoniae,
the localization of several PBPs to the zone of PG synthesis is controlled by PBP3, a carboxy-
peptidase that cleaves the terminal D-Ala from pentapeptide chains [67]. In the absence of
PBP3, pentapeptide substrates accumulate over the cell surface, causing several PBPs to delo-
calize to these zones of potential PG synthesis [67,68]. The localization of PBP3 was reported
to be either on the whole cell surface, including the division site [68], or only on the cell surface
but occluded from the division site [67]. Although the localization of PBP3 is not resolved, it is
clear that PBP3 controls the availability of PG precursors and thus localization of PG synthesis.
S. aureus and S. pneumoniae do not contain MreB, but in organisms where MreB is present,
substrate availability is also important, strongly suggesting that PBPs are not just tethered to
the PG synthesis complex through FtsZ and/or MreB, but in addition require the presence of
(and the capability to bind to) substrate to localize at the right site. The E. coli carboxypeptidase
PBP5 delocalizes from the division site, where it is most active, when its active site is mutated,
and it accumulates even more at the division site when cell wall synthesis along the lateral wall
is inhibited [69]. In Caulobacter crescentus, PBP3 delocalizes when its active site is mutated
[70]. Key components of the B. subtilis elongasome, PBP2A and PbpH, are recruited to clusters
of LipidII when LipidII is actively clustered in nonphysiological domains in the membrane (Fig
5) [71]. The recruitment to LipidII patches was strictly dependent on LipidII, as PBP2A and
PbpH did not delocalize in cells that were depleted for LipidII or when MreB was delocalized
by a collapse of the membrane potential [71]. Combined, these studies provide a strong indica-
tion that the presence of LipidII functions as a targeting signal for peptidoglycan synthesis
proteins.
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Concluding Remarks
Despite the great progress made in the last years, many questions on LipidII biology remain.
The identification of various LipidII flippases opens up a new field of study and will hopefully
lead to the elucidation of the molecular mechanism(s) of LipidII flipping. The proposed roles
of LipidII in organizing cytoskeletal proteins and peptidoglycan synthesis complexes on both
sides of the membrane require a combination of biochemical and cell biology approaches to
fully understand to which degree LipidII plays an active role in this organization, or whether
LipidII just happens to be at the right place at the right time. Finally, the discovery of teixobac-
tin has again underscored the importance of LipidII as a target for antibacterials that are not
(very) susceptible to rapid resistance development. Hopefully, more LipidII-targeting com-
pounds with promise for clinical use will be discovered in the near future.
Fig 5. Clustering of LipidII in nonphysiological domains leads to recruitment of elongation-specific
PBPs.Under normal circumstances, LipidII (stained with fluorescent vancomycin [Van-FL], green) and
RFP-PBP2A (red) co-localize at the septum (yellow in control, panel A) and the lateral wall. When LipidII is
clustered into nonphysiological domains with PP-nisin, RFP-PBP2A follows LipidII in 94% of the cases when
cells exhibit both LipidII and PBP2A spots (panel B, arrows, strong co-localization; arrowheads, co-
localization but weak Van-FL signal). (Adapted from The localization of key Bacillus subtilis penicillin binding
proteins during cell growth is determined by substrate availability, Lages MC, Beilharz K, Morales Angeles D,
Veening JW, Scheffers DJ, Environmental Microbiology 15, 3272–3281 [2013], JohnWiley & Sons, Inc.
http://onlinelibrary.wiley.com/doi/10.1111/1462-2920.12206/abstract.)
doi:10.1371/journal.ppat.1005213.g005
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